[1] CAI Y, ZHANG J, LIANG J, et al. The Burden of Rheumatoid Arthritis: Findings from the 2019 Global Burden of Diseases Study and Forecasts for 2030 by Bayesian Age-Period-Cohort Analysis. J Clin Med. 2023;12(4):1291.
[2] BACKLUND RT, DRAKE I, BERGSTROM U, et al. Adherence to Dietary Guidelines, and the Risk of Developing Rheumatoid Arthritis: Results from a Nested Case-control Study. Rheumatology (Oxford). 2024;63(2):407-413.
[3] GU P, PU B, LIU T, et al. Appraising Causal Risk and Protective Factors for Rheumatoid Arthritis. Bone. Joint Res. 2023;12(9):601-614.
[4] ALEXANDRE A, SA-COUTO D, BRANDAO M, et al. Subclinical Left Ventricular Dysfunction in. Rheumatoid Arthritis: Findings from the Prospective Porto-RA Cohort. Clin Res Cardiol. 2024. doi:10.1007/s00392-024-02548-6.
[5] LYU Q, MA L, LIU H, et al. Meta-analysis of Risk Factors for Cardiovascular Disease in Patients with Rheumatoid Arthritis. Medicine (Baltimore). 2023;102(45): e35912.
[6] VOS TLS AC. Global Incidence, Prevalence, Years Lived with Disability (YLDs), Disability-adjusted Life-years (DALYs), and Healthy Life Expectancy (HALE) for 371 Diseases and Injuries in 204 Countries and Territories and 811 Subnational Locations, 1990-2021: a Systematic Analysis for the Global Burden of Disease Study 2021. Lancet. 2024; 403(10440):2133-2161.
[7] CORRAO S, CALVO L, GIARDINA A, et al. Rheumatoid Arthritis, Cardiometabolic Comorbidities, and Related Conditions: Need to Take Action. Front Med (Lausanne). 2024;11:1421328.
[8] POUDEL S, GHIMIRE M, SHRESTHA K, et al. Impact of Rheumatoid Arthritis on Hospitalized. Inflammatory Bowel Disease Patients: Study of Demographics, Clinical Characteristics and Outcomes. Cureus. 2024;16(7):e65011.
[9] KLINGENBERG R, LUSCHER TF. Rheumatoid Arthritis and Coronary Atherosclerosis: Two Cousins. Engaging in a Dangerous Liaison. Eur Heart J. 2015;36(48):3423-3425.
[10] LOVERGROVE CE, HOWLES SA, FURNISS D, et al. Causal Inference in Health and Disease: a Review of the Principles and Applications of Mendelian Randomization. J Bone Miner Res. 2024;39(11):1539-1552.
[11] MARCHEV AS, VASILEVA LV, AMIROVA KM, et al. Metabolomics and Health: from Nutritional Crops. and Plant-based Pharmaceuticals to Profiling of Human Biofluids. Cell Mol Life Sci. 2021;78(19-20): 6487-6503.
[12] PSYCHOGIOS N, HAU DD, PENG J, et al. The Human Serum Metabolome. PLoS One. 2011;6(2):e16957.
[13] GUPTA V, WALIA GK, SACHDEVA MP. ‘Mendelian Randomization’: an Approach for Exploring Causal. Relations in Epidemiology. Public Health. 2017;145:113-119.
[14] BURGESS S, CRONJE HT. Incorporating Biological and Clinical Insights into Variant Choice for Mendelian Randomisation: Examples and Principles. eGastroenterology. 2024;2(1):e100042.
[15] CAO Y, YANG Y, HU Q, et al. Identification of Potential Drug Targets for Rheumatoid Arthritis from Genetic Insights: a Mendelian Randomization Study. J Transl Med. 2023; 21(1):616.
[16] ARNETT FC, EDWORTHY SM, BLOCH DA, et al. The American Rheumatism Association 1987 Revised. Criteria for the Classification of Rheumatoid Arthritis. Arthritis Rheum. 1988;31(3):315-324.
[17] CHEN Y, LU T, PETTERSSON-KYMMER U, et al. Genomic Atlas of the Plasma Metabolome Prioritizes. Metabolites Implicated in Human Diseases. Nat Genet. 2023;55(1):44-53.
[18] ZHAO JH, STACEY D, ERIKSSON N, et al. Author Correction: Genetics of Circulating Inflammatory. Proteins Identifies Drivers of Immune-mediated Disease Risk and Therapeutic Targets. Nat Immunol. 2023; 24(11):1960.
[19] BURGESS S, SMALL DS, THOMPSON SG. A Review of Instrumental Variable Estimators for Mendelian. Randomization. Stat Methods Med Res. 2017;26(5):2333-2355.
[20] DALAL T, PATEL CJ. PYPE: A Pipeline for Phenome-wide Association and Mendelian Randomization in Investigator-driven Biobank Scale Analysis. Patterns (N Y). 2024; 5(6):100982.
[21] TIAN H, PATEL A, BURGESS S. Estimating Time-Varying Exposure Effects Through Continuous-Time. Modelling in Mendelian Randomization. Stat Med. 2024.doi: 10.1002/sim.10222.
[22] GRANT AJ, BURGESS S. A Bayesian Approach to Mendelian Randomization Using Summary Statistics in the Univariable and Multivariable Settings with Correlated Pleiotropy. Am J Hum Genet. 2024;111(1):165-180.
[23] QIAN Y, HE Z, ZHAO SS, et al. Genetically Determined Circulating Levels of Cytokines and the Risk of. Rheumatoid Arthritis. Front Genet. 2022;13:802464.
[24] BURGESS S, BOEDEN J, FALL T, et al. Sensitivity Analyses for Robust Causal Inference from Mendelian. Randomization Analyses with Multiple Genetic Variants. Epidemiology. 2017;28(1):30-42.
[25] KARPOUZAS GA, ESTIS J, REZAEIAN P, et al. High-sensitivity Cardiac Troponin I is a Biomarker for. Occult Coronary Plaque Burden and Cardiovascular Events in Patients with Rheumatoid Arthritis. Rheumatology (Oxford). 2018;57(6):1080-1088.
[26] LOGSTRUP BB, OLESEN K, MASIC D, et al. Impact of Rheumatoid Arthritis on Major Cardiovascular Events in Patients with and without Coronary Artery Disease. Ann Rheum Dis. 2020;79(9):1182-1188.
[27] AMBROSINO P, LUPOLI R, DI MINNO A, et al. Subclinical Atherosclerosis in Patients with Rheumatoid. Arthritis. A Meta-analysis of Literature Studies. Thromb Haemost. 2015;113(5):916-930.
[28] BEDEKOVIC D, BOSNJAK I, ŠARIC S, et al. Role of Inflammatory Cytokines in Rheumatoid Arthritis and Development of Atherosclerosis: A Review. Medicina (Kaunas). 2023;59(9):1550.
[29] BOETERS DM, BURGERS LE, TOES RE, et al. Does Immunological Remission, Defined as Disappearance of Autoantibodies, Occur with Current Treatment Strategies? A Long-term Follow-up Study in Rheumatoid Arthritis Patients who Achieved Sustained DMARD-free Status. Ann Rheum Dis. 2019; 78(11):1497-1504.
[30] PACCOU J, BOUDOT C, RENARD C, et al. Total Calcium-sensing Receptor Expression in Circulating Monocytes is Increased in Rheumatoid Arthritis Patients with Severe Coronary Artery Calcification. Arthritis Res Ther. 2014;16(5):412.
[31] MANGONI AA, TOMMASI S, SOTGIA S, et al. Asymmetric Dimethylarginine: a Key Player in the Pathophysiology of Endothelial Dysfunction, Vascular Inflammation and Atherosclerosis in Rheumatoid Arthritis? Curr Pharm Des. 2021;27(18):2131-2140.
[32] KIM EY, MOUDGIL KD. Immunomodulation of Autoimmune Arthritis by Pro-inflammatory Cytokines. Cytokine. 2017;98: 87-96.
[33] SERDAR CC, CIHAN M, YUCEL D, et al. Sample size, Power and Effect Size Revisited: Simplified and. Practical Approaches in Pre-clinical, Clinical and Laboratory Studies. Biochem Med (Zagreb). 2021;31(1):10502.
[34] AIT-OUFELLA H, LIBBY P. Inflammation and Atherosclerosis: Prospects for Clinical Trials. Arterioscler Thromb Vasc Biol. 2024; 44(9):1899-1905.
[35] OISHI Y, MANABE I. Macrophages in Age-related Chronic Inflammatory Diseases. NPJ Aging Mech Dis. 2016;2:16018.
[36] WANG C, LIU S, YANG Y, et al. Interleukin-4 and Interleukin-17 are Associated with Coronary Artery Disease. Clin Cardiol. 2024; 47(2):e24188.
[37] HANNA A, FRANGOGIANNIS NG. Inflammatory Cytokines and Chemokines as Therapeutic Targets in Heart Failure. Cardiovasc Drugs Ther. 2020;34(6):849-863.
[38] BLAGOV AV, CHUROV AV, GOLOVYUK AL, et al. The Role of Metabolic Disorders in the Development of Atherosclerosis. Cell Mol Biol (Noisy-le-grand). 2024;70(9):148-155.
[39] SOLER PB, ESTRADA-CAPETILLO L, IZQUIERDO E, et al. Macrophages from the Synovium of Active. Rheumatoid Arthritis Exhibit an Activin A-dependent Pro-inflammatory Profile. J Pathol. 2015; 235(3):515-526.
[40] CHEN W, FANG Y, WANG H, et al. Role of Chemokine Receptor 2 in Rheumatoid Arthritis: A Research. Update. Int Immunopharmacol. 2023;116:109755.
[41] PARK E, IQBAL R, GILES JT, et al. Use of Methotrexate and TNF Inhibitors in Patients with Rheumatoid Arthritis-associated Interstitial Lung Disease: a Survey of Rheumatologists. Clin Rheumatol. 2024; 43(9):3029-3032.
[42] KARPOUZAS GA, ORMSETH SR, HERNANDEZ E, et al. Impact of Cumulative Inflammation, Cardiac. Risk Factors, and Medication Exposure on Coronary Atherosclerosis Progression in Rheumatoid Arthritis. Arthritis Rheumatol. 2020;72(3):400-408.
[43] YIN X, ZHANG Y, ZOU J, et al. Association of the Systemic Immune-inflammation Index with All-cause and Cardiovascular Mortality in Individuals with Rheumatoid Arthritis. Sci Rep. 2024;14(1):15129.
[44] FERT-BOBER J, DARRAH E, ANDRADE F. Insights into the Study and Origin of the Citrullinome in Rheumatoid Arthritis. Immunol Rev. 2020;294(1):133-147.
[45] ALMEIDA-SANTIAGO C, QUEVEDO-ABELEDO JC, HERNANDEZ V, et al. Circulating Interleukin-6 and Cardiovascular Disease Risk in Patients with Rheumatoid Arthritis with Low Disease Activity due to Active Therapy. Clin Exp Rheumatol. 2023;41(7):1537-1543.
[46] ROUBILLE C, RICHER V, STARNINO T, et al. The Effects of Tumour Necrosis Factor Inhibitors, Methotrexate, Mon-steroidal Anti-inflammatory Drugs and Corticosteroids on Cardiovascular Events in Rheumatoid Arthritis, Psoriasis and Psoriatic Arthritis: a Systematic Review and Meta-analysis. Ann Rheum Dis. 2015;74(3):480-489.
[47] ZHANG J, XIE F, YUN H, et al. Comparative Effects of Biologics on Cardiovascular Risk among Older Patients with Rheumatoid Arthritis. Ann Rheum Dis. 2016;75(10): 1813-1818.
[48] FERRAZ-AMARO I, GONZALEZ-GAY MA, GARCRIA -DOPICO JA, et al. Cholesteryl Ester Transfer Protein in Patients with Rheumatoid Arthritis. J Rheumatol. 2013; 40(7):1040-1047.
[49] BARBATI C, VOMERO M, COLASANTI T, et al. TNFα Expressed on the Surface of Microparticles Modulates Endothelial Cell Fate in Rheumatoid Arthritis. Arthritis Res Ther. 2018;20(1):273.
[50] ZIMMERMAN MC, CLEMENS DL, DURYEE MJ, et al. Direct Antioxidant Properties of Methotrexate: Inhibition of Malondialdehyde-acetaldehyde-protein Adduct Formation and Superoxide Scavenging. Redox Biol. 2017;13:588-593.
[51] DAVIDA L, PONGRACZ V, MOHAMED EA, et al. A Prospective, Longitudinal Monocentric Study on Laser Doppler Imaging of Microcirculation: Comparison with Macrovascular Pathophysiology and Effect of Adalimumab Treatment in Early Rheumatoid Arthritis. Rheumatol Int. 2020; 40(3):415-424.
|